




IFFIm increases its most recent bond by US\$ 250 million



The tap on the October 2024 bond makes this issue IFFIm's largest ever, with proceeds of US\$ 1.25 billion for Gavi, the Vaccine Alliance. The transaction, executed successfully during volatile market conditions, provides important additional support for Gavi's life-saving vaccine programmes.

[Read more](#)

Latest articles



HPV: an essential vaccine saving women's lives

The HPV vaccine protects girls and women against cervical cancer and is one of the most effective preventions for cancer in the world. As of December 2024, IFFIm has contributed over US\$ 132.4 million to the HPV programme — more than 22% of Gavi's total resources for the vaccine.

Learn more about how the HPV vaccine works and why it is so essential.

[Watch the video](#)



The UK's pioneering role in global health through IFFIm: Building on a legacy and continuing to lead

As a founding donor of IFFIm, the UK has played a pivotal role in transforming global health through innovative finance. In this first in a series of IFFIm donor profiles, explore how the UK's leadership helped launch IFFIm and continues to shape the future of immunisation and health equity worldwide.

[Read more](#)



Rachel Turner and Ingrid van Wees shine spotlight on IFFIm

As donor countries are confronting growing budget pressures, IFFIm is more relevant than ever in global development financing. IFFIm's history, impact and future potential was the subject of recent conference panels featuring IFFIm Board members Rachel Turner in London and Ingrid van Wees in Amsterdam.

[Read more](#)